As of 2025-10-20, the Relative Valuation of Madrigal Pharmaceuticals Inc (MDGL) is (271.91) USD. This relative valuation is based on P/E multiples. With the latest stock price at 438.90 USD, the upside of Madrigal Pharmaceuticals Inc based on Relative Valuation is -162.0%.
The range of the Relative Valuation is (253.70) - (305.80) USD.
Note: valuation result may not be accurate due to the company's negative earnings.
| Range | Selected | |
| Trailing P/E multiples | 20.1x - 26.9x | 24.3x |
| Forward P/E multiples | 16.7x - 24.2x | 18.7x |
| Fair Price | (253.70) - (305.80) | (271.91) |
| Upside | -157.8% - -169.7% | -162.0% |
| Date | P/E |
| 2025-10-17 | -34.70 |
| 2025-10-16 | -34.96 |
| 2025-10-15 | -34.27 |
| 2025-10-14 | -34.56 |
| 2025-10-13 | -33.82 |
| 2025-10-10 | -33.97 |
| 2025-10-09 | -33.87 |
| 2025-10-08 | -34.55 |
| 2025-10-07 | -34.50 |
| 2025-10-06 | -34.97 |
| 2025-10-03 | -35.03 |
| 2025-10-02 | -35.55 |
| 2025-10-01 | -35.51 |
| 2025-09-30 | -36.27 |
| 2025-09-29 | -35.04 |
| 2025-09-26 | -33.54 |
| 2025-09-25 | -33.45 |
| 2025-09-24 | -33.75 |
| 2025-09-23 | -35.05 |
| 2025-09-22 | -34.80 |
| 2025-09-19 | -34.79 |
| 2025-09-18 | -34.85 |
| 2025-09-17 | -33.01 |
| 2025-09-16 | -33.77 |
| 2025-09-15 | -33.65 |
| 2025-09-12 | -34.18 |
| 2025-09-11 | -34.75 |
| 2025-09-10 | -34.01 |
| 2025-09-09 | -35.48 |
| 2025-09-08 | -35.88 |
| 2025-09-05 | -34.23 |
| 2025-09-04 | -34.10 |
| 2025-09-03 | -34.42 |
| 2025-09-02 | -34.48 |
| 2025-08-29 | -34.62 |
| 2025-08-28 | -34.57 |
| 2025-08-27 | -33.61 |
| 2025-08-26 | -33.59 |
| 2025-08-25 | -32.60 |
| 2025-08-22 | -32.79 |
| 2025-08-21 | -32.19 |
| 2025-08-20 | -30.97 |
| 2025-08-19 | -30.01 |
| 2025-08-18 | -30.95 |
| 2025-08-15 | -29.24 |
| 2025-08-14 | -29.36 |
| 2025-08-13 | -29.53 |
| 2025-08-12 | -28.39 |
| 2025-08-11 | -27.64 |
| 2025-08-08 | -27.34 |